S.M.A.I.O S.A.
EEURONEXT:ALSMA5.50
EUR
0.00
(0.00%)
ISIN
FR0014005I80
Return %
Stock
S&P 500
1Y
-17.91
14.20
3Y
129.17
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Philippe Roussouly
- Full Time Employees
- 48
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Saint-Priest France
- IPO Date
- Apr 6, 2022
- Website
- smaio.com
- Similar Companies
- Business
- S.M.A.I.O S.A. is a medical technology company specializing in the design, development, and commercialization of software and implant solutions for complex spine surgery and sagittal alignment restoration. Founded in 2009 and headquartered in Lyon, France, with North American commercial operations in Dallas, Texas, the company operates across Europe and the United States to serve spine surgeons, specialized hospitals, orthopedic clinics, and medical device manufacturers. S.M.A.I.O offers an integrated ecosystem known as i-Kontrol, which aligns pre-operative planning, patient-specific surgical execution, and post-operative analysis. The company's primary products and services comprise: KEOPS, a proprietary clinical database and surgical registry platform utilized for big data analytics, case documentation, and surgical outcome prediction; KEOPS Balance Analyzer 3D, an advanced 3D planning software module designed to compute patient-specific anatomical alignments and simulate surgical corrections; KEOPS-4ME, an open-access planning and custom rod software platform compatible with multi-vendor implant systems; the Kheiron Spinal Fixation System, a thoracolumbar fixation implant suite consisting of pedicle screws, cross-links, hooks, and surgical instruments; K-ROD, customized, patient-specific pre-bent surgical rods manufactured according to digital pre-operative plans; and i-LEARN, a specialized clinical training, mentorship, and registry management service delivered through the company's Sagittal Alignment Academy. In recent developments, S.M.A.I.O expanded its commercial footprint in the United States by entering into strategic distribution partnerships with Highridge Medical and Orthofix to deploy its KEOPS-4ME open platform across major hospital networks. In early 2025, S.M.A.I.O and NuVasive mutually concluded their historical development and licensing collaboration following NuVasive's corporate acquisition, transitioning S.M.A.I.O toward an independent, multi-partner commercialization model. To support its continued commercial rollout and operational growth in the North American market, the company strengthened its financial position through a 3.6 million euro capital increase in March 2026 alongside 2.0 million euros in non-dilutive financing facilities.